Detalles de la búsqueda
1.
Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.
J Infect Dis
; 227(11): 1333-1334, 2023 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36520978
2.
Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.
J Med Econ
; 26(1): 630-643, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37067826
3.
A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.
PLoS One
; 18(8): e0289828, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37561741
4.
Identifying the research, advocacy, policy and implementation needs for the prevention and management of respiratory syncytial virus lower respiratory tract infection in low- and middle-income countries.
Front Pediatr
; 10: 1033125, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36440349
5.
Substituting Doxorubicin with nonpegylated liposomal Doxorubicin for the treatment of early breast cancer: results of a retrospective study.
Int J Breast Cancer
; 2014: 984067, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24527216
6.
Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer.
Clin Breast Cancer
; 14(2): 85-93, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24325950
7.
Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.
Clin Rheumatol
; 32(11): 1605-12, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23835658
Resultados
1 -
7
de 7
1
Próxima >
>>